Anti-HER2 antibody DOTA-pertuzumab conjugation and labelling studies with Ac-225
The overexpression of human epidermal growth factor receptor type 2 (HER2) is observed in various tumours. It serves as a prognostic and predictive biomarker. Targeting of HER2 receptors by monoclonal antibodies such as trastuzumab or pertuzumab is used in immunotherapy of these diseases .
The similar targeting concept can and has been applied in radioimmunotherapy. In recent years the most focus is placed on use of alpha-emitting radionuclides which makes radioimmunotherapy a part of targeted alpha-particle therapy. The most studied radionuclides are therefore At-211, Pb-212 or Ac-225.
The use of Ac-225 can be especially beneficial thanks to the enormous energy released per one decay. Even though, this radionuclide has already been studied in labelling of various monoclonal antibodies and nanobodies, labelling of pertuzumab monoclonal antibody has been neglected.
FIALOVA Katerina;
ONDRAK Lukas;
VLK M.;
KOZEMPEL J.;
PRUSZYNSKI Marek;
BRUCHERTSEIFER Frank;
MORGENSTERN Alfred;
2022-12-16
SPRINGER
JRC129441
1619-7070 (online),
https://publications.jrc.ec.europa.eu/repository/handle/JRC129441,
10.1007/s00259-022-05924-4 (online),
Additional supporting files
| File name | Description | File type | |
|---|
